Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,614 across all filing types
Latest filing 2026-01-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress and release of external guarantees. It includes details about board meetings, shareholder meetings, and the status of guarantees related to subsidiaries. The document is relatively short (643 characters) and focuses on a specific corporate action related to guarantees, not a full financial report or audit. It does not contain financial statements or detailed financial analysis. It is a regulatory announcement about corporate guarantees, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Capital Update.
2026-01-19 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2026 first extraordinary shareholders meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, voting methods, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2418 characters), consistent with a voting results announcement rather than a full report or presentation.
2026-01-16 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2026年第一次临时股东会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, procedures, attendance, voting, and legality of a company's 2026 first extraordinary general meeting (临时股东会). It details the legal compliance of the meeting's call, attendance, voting procedures, and results. It does not contain financial statements or management discussion of financial results. It is not a report of financial performance but a legal opinion on the shareholder meeting's procedural legality. This type of document is best classified as a Regulatory Filing (RNS) because it is a legal compliance document related to corporate governance and shareholder meetings, not a direct report like AGM materials or voting results announcements. The document length and content confirm it is not a brief announcement but a full legal opinion, still fitting RNS rather than AGM-R or DVA, as it does not present AGM materials or official voting results announcements but a legal opinion on the meeting's legality.
2026-01-16 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding abnormal stock price fluctuations over two trading days. It includes statements confirming no undisclosed material information, no insider trading, and no changes in business conditions. The document is short (1011 characters) and serves as a regulatory disclosure about stock trading activity and compliance with disclosure rules. It does not contain financial statements, management discussion, or detailed report data. It is not an annual or interim report, earnings release, or any detailed financial or governance report. It is a regulatory announcement related to stock price movement and information disclosure compliance, fitting the category of Regulatory Filings (RNS).
2026-01-14 Chinese
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress and release of external guarantees related to a subsidiary's asset transfer and loan collateral. It includes details about the guarantee situation, progress, and cumulative guarantee balance. The document is relatively short (748 characters) and serves as an update on a specific financial guarantee matter rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. This type of announcement fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-06 Chinese
关于为全资子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its wholly-owned subsidiary. It details the guarantee amount, contract terms, and cumulative guarantee exposure. The document is a formal disclosure about a financial guarantee arrangement, not a financial report or earnings release. It does not contain financial statements or management discussion but is a regulatory announcement about a specific financing-related guarantee. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2026-01-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.